BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 30030836)

  • 1. Notch in Leukemia.
    McCarter AC; Wang Q; Chiang M
    Adv Exp Med Biol; 2018; 1066():355-394. PubMed ID: 30030836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors.
    Aste-Amézaga M; Zhang N; Lineberger JE; Arnold BA; Toner TJ; Gu M; Huang L; Vitelli S; Vo KT; Haytko P; Zhao JZ; Baleydier F; L'Heureux S; Wang H; Gordon WR; Thoryk E; Andrawes MB; Tiyanont K; Stegmaier K; Roti G; Ross KN; Franlin LL; Wang H; Wang F; Chastain M; Bett AJ; Audoly LP; Aster JC; Blacklow SC; Huber HE
    PLoS One; 2010 Feb; 5(2):e9094. PubMed ID: 20161710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure of the Notch1-negative regulatory region: implications for normal activation and pathogenic signaling in T-ALL.
    Gordon WR; Roy M; Vardar-Ulu D; Garfinkel M; Mansour MR; Aster JC; Blacklow SC
    Blood; 2009 Apr; 113(18):4381-90. PubMed ID: 19075186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Murine Pten(-/-) T-ALL requires non-redundant PI3K/mTOR and DLL4/Notch1 signals for maintenance and γc/TCR signals for thymic exit.
    Hagenbeek TJ; Wu X; Choy L; Sanchez-Irizarry C; Seshagiri S; Stinson J; Siebel CW; Spits H
    Cancer Lett; 2014 May; 346(2):237-48. PubMed ID: 24384093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Notch driven long non-coding RNA repertoire in T-cell acute lymphoblastic leukemia.
    Durinck K; Wallaert A; Van de Walle I; Van Loocke W; Volders PJ; Vanhauwaert S; Geerdens E; Benoit Y; Van Roy N; Poppe B; Soulier J; Cools J; Mestdagh P; Vandesompele J; Rondou P; Van Vlierberghe P; Taghon T; Speleman F
    Haematologica; 2014 Dec; 99(12):1808-16. PubMed ID: 25344525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-range enhancer activity determines Myc sensitivity to Notch inhibitors in T cell leukemia.
    Yashiro-Ohtani Y; Wang H; Zang C; Arnett KL; Bailis W; Ho Y; Knoechel B; Lanauze C; Louis L; Forsyth KS; Chen S; Chung Y; Schug J; Blobel GA; Liebhaber SA; Bernstein BE; Blacklow SC; Liu XS; Aster JC; Pear WS
    Proc Natl Acad Sci U S A; 2014 Nov; 111(46):E4946-53. PubMed ID: 25369933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The common oncogenomic program of NOTCH1 and NOTCH3 signaling in T-cell acute lymphoblastic leukemia.
    Choi SH; Severson E; Pear WS; Liu XS; Aster JC; Blacklow SC
    PLoS One; 2017; 12(10):e0185762. PubMed ID: 29023469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The NOTCH1-MYC highway toward T-cell acute lymphoblastic leukemia.
    Sanchez-Martin M; Ferrando A
    Blood; 2017 Mar; 129(9):1124-1133. PubMed ID: 28115368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High selective pressure for Notch1 mutations that induce Myc in T-cell acute lymphoblastic leukemia.
    Chiang MY; Wang Q; Gormley AC; Stein SJ; Xu L; Shestova O; Aster JC; Pear WS
    Blood; 2016 Nov; 128(18):2229-2240. PubMed ID: 27670423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The frequency of NOTCH1 variants in T-acute lymphoblastic leukemia/lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma among Jordanian patients.
    Abualhaj NZ; Dardas Z; Azab B; Ali D; Sughayer MA; Aladily TN; Ahram M
    Ann Diagn Pathol; 2019 Apr; 39():53-58. PubMed ID: 30718223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How to resist Notch-targeted T-leukemia therapy: Lineage- and MYC enhancer switch.
    Bayer M; Grosschedl R
    Mol Cell; 2022 Mar; 82(5):884-886. PubMed ID: 35245453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncogenic Notch signaling in T-cell and B-cell lymphoproliferative disorders.
    Chiang MY; Radojcic V; Maillard I
    Curr Opin Hematol; 2016 Jul; 23(4):362-70. PubMed ID: 27135981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockade of Oncogenic NOTCH1 with the SERCA Inhibitor CAD204520 in T Cell Acute Lymphoblastic Leukemia.
    Marchesini M; Gherli A; Montanaro A; Patrizi L; Sorrentino C; Pagliaro L; Rompietti C; Kitara S; Heit S; Olesen CE; Møller JV; Savi M; Bocchi L; Vilella R; Rizzi F; Baglione M; Rastelli G; Loiacono C; La Starza R; Mecucci C; Stegmaier K; Aversa F; Stilli D; Lund Winther AM; Sportoletti P; Bublitz M; Dalby-Brown W; Roti G
    Cell Chem Biol; 2020 Jun; 27(6):678-697.e13. PubMed ID: 32386594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MAFB enhances oncogenic Notch signaling in T cell acute lymphoblastic leukemia.
    Pajcini KV; Xu L; Shao L; Petrovic J; Palasiewicz K; Ohtani Y; Bailis W; Lee C; Wertheim GB; Mani R; Muthusamy N; Li Y; Meijerink JPP; Blacklow SC; Faryabi RB; Cherry S; Pear WS
    Sci Signal; 2017 Nov; 10(505):. PubMed ID: 29138297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
    Hales EC; Taub JW; Matherly LH
    Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells.
    Rao SS; O'Neil J; Liberator CD; Hardwick JS; Dai X; Zhang T; Tyminski E; Yuan J; Kohl NE; Richon VM; Van der Ploeg LH; Carroll PM; Draetta GF; Look AT; Strack PR; Winter CG
    Cancer Res; 2009 Apr; 69(7):3060-8. PubMed ID: 19318552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotactic Cues for NOTCH1-Dependent Leukemia.
    Piovan E; Tosello V; Amadori A; Zanovello P
    Front Immunol; 2018; 9():633. PubMed ID: 29666622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of activating mutations of NOTCH3 in T-cell acute lymphoblastic leukemia and anti-leukemic activity of NOTCH3 inhibitory antibodies.
    Bernasconi-Elias P; Hu T; Jenkins D; Firestone B; Gans S; Kurth E; Capodieci P; Deplazes-Lauber J; Petropoulos K; Thiel P; Ponsel D; Hee Choi S; LeMotte P; London A; Goetcshkes M; Nolin E; Jones MD; Slocum K; Kluk MJ; Weinstock DM; Christodoulou A; Weinberg O; Jaehrling J; Ettenberg SA; Buckler A; Blacklow SC; Aster JC; Fryer CJ
    Oncogene; 2016 Nov; 35(47):6077-6086. PubMed ID: 27157619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-4-dependent Jagged1 expression/processing is associated with survival of chronic lymphocytic leukemia cells but not with Notch activation.
    De Falco F; Del Papa B; Baldoni S; Sabatini R; Falzetti F; Di Ianni M; Martelli MP; Mezzasoma F; Pelullo M; Marconi P; Sportoletti P; Screpanti I; Rosati E
    Cell Death Dis; 2018 Nov; 9(12):1160. PubMed ID: 30478302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel Monoclonal Antibody against Notch1 Targets Leukemia-associated Mutant Notch1 and Depletes Therapy Resistant Cancer Stem Cells in Solid Tumors.
    Sharma A; Gadkari RA; Ramakanth SV; Padmanabhan K; Madhumathi DS; Devi L; Appaji L; Aster JC; Rangarajan A; Dighe RR
    Sci Rep; 2015 Jun; 5():11012. PubMed ID: 26046801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.